Results 151 to 160 of about 14,264 (186)
Diabetes Care, 2020 Background: The role of U300 glargine insulin for the inpatient management of type 2 diabetes (T2D) has not been determined. We compared the safety and efficacy of glargine U300 vs. glargine U100 in non-critically ill patients with T2D.
Priyathama Vellanki
exaly +2 more sources
Diabetes Care, 2012 OBJECTIVE-In vivo, after subcutaneous injection, insulin glargine (21(A)-Gly-31(B)-Arg-32(B)-Arg-human insulin) is enzymatically processed into 21(A)-Gly-human insulin (metabolite 1 [M1]). 21(A)-Gly-des-30(B)-Thr-human insulin (metabolite 2 [M2]) is also
Reinhard H A Becker +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Therapeutics, 2001
In diabetes mellitus, the clinical goal of intensive glycemic control (lowering blood glucose concentrations to normal or near-normal levels) has been hindered by the lack of insulin regimens that duplicate the basal-bolus secretion of insulin by the healthy pancreas. In particular, intensive therapy has been associated with a risk of hypoglycemia.This
R K, Campbell +3 more
openaire +2 more sources
In diabetes mellitus, the clinical goal of intensive glycemic control (lowering blood glucose concentrations to normal or near-normal levels) has been hindered by the lack of insulin regimens that duplicate the basal-bolus secretion of insulin by the healthy pancreas. In particular, intensive therapy has been associated with a risk of hypoglycemia.This
R K, Campbell +3 more
openaire +2 more sources
An overview of insulin glargine
Diabetes/Metabolism Research and Reviews, 2002Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Accordingly, it mimics more closely the natural physiological profile of basal endogenous insulin secretion than do traditional extended-acting insulins such as NPH insulin.
Philip D, Home, Simon G, Ashwell
openaire +3 more sources